A COVID-19 vaccine is administered in Toronto on Monday, Dec. 14, 2020. THE CANADIAN PRESS/Frank Gunn

A COVID-19 vaccine is administered in Toronto on Monday, Dec. 14, 2020. THE CANADIAN PRESS/Frank Gunn

Clinical trials start for Canadian COVID-19 vaccine candidate

Dubbed COVAC-2, the vaccine hopeful was developed by the Vaccine and Infectious Disease Organization

Clinical trials have begun for another Canadian-made COVID-19 vaccine candidate, with three people receiving an initial dose on Wednesday.

The Canadian Center for Vaccinology says the first of 108 healthy adult volunteers received injections in Halifax. The placebo-controlled study will administer two doses to each volunteer, 28 days apart.

“It’s a product of Canadian science, so it bodes well for the ability to make vaccines here. We all want to have vaccine manufacturing capacity in Canada,” said Dr. Joanne Langley, a vaccine researcher with the centre.

She said that the pace of testing is careful, as different age groups, from younger to older, receive varying doses in a process that will unfold over the next two months.

Dubbed COVAC-2, the vaccine hopeful was developed by the Vaccine and Infectious Disease Organization, or VIDO, at the University of Saskatchewan in Saskatoon.

It’s the first of two subunit vaccines by VIDO to enter clinical testing. Subunit vaccines contain purified viral proteins that are not infectious, and employ technology already used in vaccines for hepatitis, diphtheria, and whooping cough.

Darryl Falzarano, a vaccine researcher at VIDO, said he’s hoping that his institute’s promising tests on ferrets and hamsters will translate into safe and effective results in the human testing phase.

“Safety is the primary indicator (in the first phase) but you will also be looking at immune response,” he said.

Langley said the testing in the first phase is to determine safety to humans, and the participants will keep a diary that measure any pain or redness of the arm. The trial will also measure antibody responses, she said.

The next step would be to do trials at multiple sites around the country.

It is only in Phase 3 that the vaccine is compared against a placebo or another vaccine to see how well it protects against COVID-19, said Langley.

She said the entire vaccine testing process, if all went well, could take about nine months, adding that is a “very wishful, optimistic scenario.”

VIDO has said in a news release the product doesn’t need ultra-cold storage temperatures like synthetic messenger RNA or mRNA products. The two Health Canada-approved vaccines by Moderna and Pfizer-BioNTech each require special distribution and storage procedures that have complicated their rollout.

It follows the launch last month of clinical trials for a prospective vaccine by Calgary’s Providence Therapeutics, and last year’s launch of trials for a vaccine hopeful by Quebec City’s Medicago.

VIDO’s vaccine antigen – a molecule that triggers an immune response – was produced at Quebec-based Biodextris using a cell line from the National Research Council of Canada.

Development help also came from partners around the world, including Seppic in France and the Vaccine Formulation Institute in Switzerland.

At the same time, VIDO is building a manufacturing facility on the USask campus that could produce up to 40 million vaccine doses, but it wasn’t certain if that would include VIDO’s product. Construction is expected to be completed late this year.

Falzarano said the team in Saskatoon is excited the process is beginning, as this form of vaccine can be mass produced at a rapid rate if successful.

“It’s only the beginning of a multi-step process, but at least we’ve gotten to this milestone,” he said.

ALSO READ: Experts say race for COVID drugs dogged by false promises, lack of co-ordination

Michael Tutton and Cassandra Szklarski, The Canadian Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

Coronavirusvaccines

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

(Black Press file photo)
Blackfalds continuing its fight for a registries office

The Town of Blackfalds has been fighting for a Registry Service outlet for roughly a decade

Alberta Premier Jason Kenney said Thursday that the province may consider a regional approach to loosening COVID-19 restrictions if numbers continue to decline. (photo by Chris Schwarz/Government of Alberta)
Province further easing health restrictions

Numbers of people hospitalized and in intensive care has dropped dramatically, says premier

Eric Rajah, co-founder of A Better World. (Photo Submitted)
Two Lacombe residents recieve award from Governor General for chairty work

Eric Rajah and Brian Leavitt co-founded A Better World, a charity which started in Lacombe in 1990

A ” Justice for Jeff” T-shirt. (Photo submitted)
Rally to be held outside courthouse for man slain in Lacombe

Sentencing for accused charged with manslaughter with a firearm set for March 4 in Red Deer

File photo
Alberta’s central zone has 670 active cases

301 new cases identified Sunday

Bookings for COVID-19 vaccines for people age 75 or older start Wednesday. (File photo by THE CANADIAN PRESS)
Updated: Delays for seniors booking for vaccine appointments

By 9:20 a.m. Wednesday, 4,500 seniors had booked their appointments

A locally-produced video project aims to preserve Canada’s railway history

‘Railways have been an integral part of Canadian history since 1836’

Ryan Jake Applegarth of Ponoka, 28, is scheduled to appear at Ponoka Provincial Court on March 12, 2021. (File photo)
Discussions about justice continue as Ponoka murder victim’s case proceeds

Reaction to comments Ponoka Staff Sgt. Chris Smiley made to town council last month

Dr. Stanley Read
Hometown Bashaw doctor recognized with alumni award for AIDS work

Dr. Stanley Read, born and raised in Bashaw, is considered a global health leader

A copy of the book “And to Think That I Saw It on Mulberry Street,” by Dr. Seuss, rests in a chair, Monday, March 1, 2021, in Walpole, Mass. Dr. Seuss Enterprises, the business that preserves and protects the author and illustrator’s legacy, announced on his birthday, Tuesday, March 2, 2021, that it would cease publication of several children’s titles including “And to Think That I Saw It on Mulberry Street” and “If I Ran the Zoo,” because of insensitive and racist imagery. (AP Photo/Steven Senne)
6 Dr. Seuss books won’t be published for racist images

Books affected include McElligot’s Pool, On Beyond Zebra!, Scrambled Eggs Super! and The Cat’s Quizzer

AstraZeneca’s vaccine ready for use at the vaccination centre in Apolda, Germany, Sunday, Feb. 28, 2021. THE CANADIAN PRESS/Michael Reichel/dpa via AP
National panel advises against using Oxford-AstraZeneca’s COVID-19 vaccine on seniors

NACI panel said vaccines from Pfizer and Moderna are preferred for seniors ‘due to suggested superior efficacy’

Shipping containers are seen at the Fairview Cove Container Terminal in Halifax on Friday, Aug. 25, 2017. THE CANADIAN PRESS/Andrew Vaughan
Canadian economy contracted 5.4 per cent in 2020, worst year on record

Drop was largely due to shutdowns in the spring as COVID began to spread

THE CANADIAN PRESS/Jeff McIntosh
Time to check the mail: Every household to receive a Canada Post postcard this spring

Postcard can be mailed for free to any address in Canada

A cross-country skier glides along the banks of the Ottawa River in Ottawa on Thursday, Feb. 25, 2021. Canadians across the country can look forward to a mild spring peppered with the odd winter flashback throughout the first part of the season, according to predictions from one prominent national forecaster. THE CANADIAN PRESS/Sean Kilpatrick
Mild spring with some wintry blasts predicted for most of Canada: Weather Network

Weather Network is forecasting a slower than average start to spring in British Columbia

Most Read